PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Profitability reveals how effectively the business turns revenues into profits. Higher and improving margins or returns on capital suggest a durable competitive advantage, supporting a stronger intrinsic valuation.
-36.86%
Negative ROE while AVXL stands at 30.51%. Joel Greenblatt would investigate capital misallocation or uncompetitive positioning.
80.34%
Positive ROA while AVXL shows negative. Mohnish Pabrai might see this as a clear operational edge.
395.15%
ROCE above 1.5x AVXL's 34.03%. David Dodd would check if sustainable process or technology advantages are in play.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.